Pyrazinamide–isoniazid hybrid: synthesis optimisation, characterisation, and antituberculous activity-Reference-Cited by-同舟云学术

Pyrazinamide–isoniazid hybrid: synthesis optimisation, characterisation, and antituberculous activity

Published:2022-06-29 Issue:3 Volume:50 Page:16-23
ISSN:2357-3791
Container-title:Revista Colombiana de Química
language:
Short-container-title:Rev. Colomb. Quim.

Author:

Valderrama Negrón Ana Cecilia,Ramirez Panti Rocio I.,Aliaga Paucar Christian M.,Grandez Arias Fernando,Sheen Cortovaria Patricia,Zimic Peralta Mirko Juan,Cauna Orocollo Yudith

Abstract

Over time, the effective resistance mechanisms to various first- and second-line drugs against the disease of tuberculosis make its treatment extremely difficult. This work presents a new approach to synthesizing a hybrid of antituberculosis medications: isoniazid (INH) and pyrazinamide (PZA). The synthesis was performed using ultrasound-assisted synthesis to obtain an overall yield of 70%, minimizing the reaction time from 7 to 1 h. The evaluation of the biological activity of the hybrid (compound 2) was tested using the tetrazolium microplate assay (TEMA), showing inhibition in the growth of Mycobacterium tuberculosis H37Rv at a concentration of 0.025 mM at pH 6.0 and 6.7.

Publisher

Universidad Nacional de Colombia

Subject

General Chemistry

Reference42 articles.

1. “OMS | Informe mundial sobre la tuberculosis,” WHO, 2019.

2. D. S. R. Deepak Kumara, Garima Khareb, Beenaa, Saqib Kidwaic, Anil K. Tyagib, Ramandeep Singhc, “Novel isoniazid-amidoether derivatives: Synthesis, characterization and antimycobacterial activity evaluation,” Royal Society of Chemistry, vol. 3, pp. 10715–10722, 2014, doi: 10.1039/C4MD00288A.

3. R. N. Garner, C. G. Pierce, C. R. Reed, and W. W. Brennessel, “Photoinitiated treatment of Mycobacterium using Ru(II) isoniazid complexes,” Inorganica Chimica Acta, vol. 461, no. Ii, pp. 261–266, 2017, doi: 10.1016/j.ica.2017.02.031.

4. A. E. Ali, G. S. Elasala, E. A. Mohamed, and S. A. Kolkaila, “Spectral, thermal studies and biological activity of pyrazinamide complexes,” Heliyon, vol. 5, no. 11, p. e02912, 2019, doi: 10.1016/j.heliyon.2019.e02912.

5. J. Laborde et al., “Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy,” Journal of Inorganic Biochemistry, vol. 179, no. July 2017, pp. 71–81, 2018, doi: 10.1016/j.jinorgbio.2017.11.013.